{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-21-007353","form_type":"8-K","ticker":"CRVS","cik":"0001626971","company_name":"Corvus Pharmaceuticals, Inc.","filed_at":"2021-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.377981+00:00","generated_at":"2026-06-28T15:45:37.215315+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Corvus Q3 net loss $10.7M, cash $76.3M; mupadolimab trials enrolling","bullets":["Net loss for Q3 2021 was $10.7M vs $9.8M in Q3 2020; R&D expenses $7.0M vs $6.6M.","Cash, equivalents and marketable securities $76.3M at Sept 30, 2021, up $32.0M from Dec 31, 2020; FY 2021 cash burn guided ~$36M.","Two Phase 1b/2 trials of mupadolimab + pembrolizumab enrolling: relapsed NSCLC (n=15) and HPV+ HNSCC (n=15); results expected 2022.","Angel Pharma received IND approval in China for CPI-818 Phase 1/1b in T-cell lymphoma; trial to open early 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-21-007353","json":"https://secwatch.observer/filing/0001171843-21-007353.json","markdown":"https://secwatch.observer/filing/0001171843-21-007353.md","text":"https://secwatch.observer/filing/0001171843-21-007353.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1626971/000117184321007353/0001171843-21-007353-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1626971/000117184321007353/f8k_110121.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T15:45:37.215315+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}